443 related articles for article (PubMed ID: 21839683)
21. High-density lipoprotein subfractions--what the clinicians need to know.
Pirillo A; Norata GD; Catapano AL
Cardiology; 2013; 124(2):116-25. PubMed ID: 23428644
[TBL] [Abstract][Full Text] [Related]
22. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
Marcil M; O'Connell B; Krimbou L; Genest J
Expert Rev Cardiovasc Ther; 2004 May; 2(3):417-30. PubMed ID: 15151487
[TBL] [Abstract][Full Text] [Related]
23. Subfractions and subpopulations of HDL: an update.
Rizzo M; Otvos J; Nikolic D; Montalto G; Toth PP; Banach M
Curr Med Chem; 2014; 21(25):2881-91. PubMed ID: 24735362
[TBL] [Abstract][Full Text] [Related]
24. Regulation of high-density lipoprotein metabolism.
Rye KA; Barter PJ
Circ Res; 2014 Jan; 114(1):143-56. PubMed ID: 24385508
[TBL] [Abstract][Full Text] [Related]
25. Is raising HDL a futile strategy for atheroprotection?
Joy T; Hegele RA
Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
[TBL] [Abstract][Full Text] [Related]
26. The paradox of dysfunctional high-density lipoprotein.
Ansell BJ; Fonarow GC; Fogelman AM
Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
[TBL] [Abstract][Full Text] [Related]
27. The potential for CETP inhibition to reduce cardiovascular disease risk.
Ansell B; Hobbs FD
Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
[TBL] [Abstract][Full Text] [Related]
28. Dual effect of hypochlorite in the modification of high density lipoproteins.
Pirillo A; Uboldi P; Catapano AL
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):447-51. PubMed ID: 21094143
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
30. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
Rosenblat M; Karry R; Aviram M
Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
[TBL] [Abstract][Full Text] [Related]
31. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins.
Malle E; Marsche G; Panzenboeck U; Sattler W
Arch Biochem Biophys; 2006 Jan; 445(2):245-55. PubMed ID: 16171772
[TBL] [Abstract][Full Text] [Related]
32. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR; Walter M; Assmann G
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
[TBL] [Abstract][Full Text] [Related]
33. Lipid disorders and their relevance to outcomes in chronic kidney disease.
Vaziri ND; Norris K
Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
[TBL] [Abstract][Full Text] [Related]
34. Metabolic and functional relevance of HDL subspecies.
Asztalos BF; Tani M; Schaefer EJ
Curr Opin Lipidol; 2011 Jun; 22(3):176-85. PubMed ID: 21537175
[TBL] [Abstract][Full Text] [Related]
35. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
36. HDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease.
Kontush A
Trends Mol Med; 2020 Dec; 26(12):1086-1100. PubMed ID: 32861590
[TBL] [Abstract][Full Text] [Related]
37. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities.
Kontush A; Therond P; Zerrad A; Couturier M; Négre-Salvayre A; de Souza JA; Chantepie S; Chapman MJ
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1843-9. PubMed ID: 17569880
[TBL] [Abstract][Full Text] [Related]
38. Acute high-density lipoprotein therapies.
Duong M; Di Bartolo BA; Nicholls SJ
Curr Opin Lipidol; 2015 Dec; 26(6):521-5. PubMed ID: 26382551
[TBL] [Abstract][Full Text] [Related]
39. [Lipoproteins containing apolipoprotein A-I and reverse transport of cholesterol].
Fruchart JC
Ann Pharm Fr; 1994; 52(3):117-23. PubMed ID: 7998758
[TBL] [Abstract][Full Text] [Related]
40. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
